Sandoz Group AG (SDZNY)

OTCMKTS · Delayed Price · Currency is USD
52.66
-0.76 (-1.42%)
Jun 24, 2025, 3:55 PM EDT
43.23%
Market Cap 22.65B
Revenue (ttm) 10.38B
Net Income (ttm) n/a
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE 15.65
Dividend 0.57 (1.09%)
Ex-Dividend Date Apr 22, 2025
Volume 354
Average Volume 32,504
Open 52.05
Previous Close 53.42
Day's Range 52.01 - 52.66
52-Week Range 35.61 - 54.49
Beta n/a
RSI 62.33
Earnings Date Aug 7, 2025

About Sandoz Group AG

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]

Sector Healthcare
Founded 1886
Employees 22,049
Stock Exchange OTCMKTS
Ticker Symbol SDZNY
Full Company Profile

Financial Performance

Financial Statements

News

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next year.

7 days ago - Fortune

Ozempic Patent Expires In Canada After Novo Nordisk Fails To Pay $450 Fee: 'It's The Second-Largest Semaglutide Market In The World,' Says Sandoz CEO Richard Saynor

Danish pharma giant Novo Nordisk A/S (NYSE: NVO) faces potential financial losses related to its blockbuster weight-loss and diabetes drug, Ozempic, due to a regulatory issue. What Happened: About a ...

8 days ago - Benzinga

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab ...

22 days ago - GlobeNewsWire

Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars

MEDIA RELEASE Pyzchiva® first ustekinumab biosimilar in Europe commercially available in pre-filled pen (autoinjector), offering improved self-administration experience for better treatment adherence ...

4 weeks ago - GlobeNewsWire

Sandoz reports Q1 2025 net sales in line with company expectations; full-year guidance confirmed

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Q1 2025 net sales of USD 2,480 million  up by 3% in constant currencies (cc); stable in USD up by 5%[1] at a comp...

7 weeks ago - GlobeNewsWire

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net reference medicine sales of USD 2.5 billion[1] Henlius to...

2 months ago - GlobeNewsWire

Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access

The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global...

2 months ago - Reuters

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG

Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...

2 months ago - GlobeNewsWire

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...

2 months ago - Benzinga

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated

2 months ago - GlobeNewsWire

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News

2 months ago - GuruFocus

Switzerland's Sandoz files antitrust lawsuit against Amgen in US

Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...

2 months ago - Reuters

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla...

2 months ago - GlobeNewsWire

Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions

La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...

2 months ago - elEconomista.es

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility

New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity. New facility replaces initial and unutilized USD 1.25 billion RCF,...

3 months ago - GlobeNewsWire

Sandoz signs landmark supply and manufacturing agreement

BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...

3 months ago - GlobeNewsWire

Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE

BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...

3 months ago - Benzinga

Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...

Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives

3 months ago - GuruFocus

US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says

The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.

3 months ago - Financial Post

Health Care Roundup: Market Talk

Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.

3 months ago - The Wall Street Journal